ACADIA Pharmaceuticals (ACAD) : Fridays money flow data in ACADIA Pharmaceuticals (ACAD) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $3.76 million, whereas, $2.33 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.61, in favor of the bulls. The total money flow into the stock was $1.43 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0.64 million. The total value of block trades done on upticks was $0.64 million. ACADIA Pharmaceuticals (ACAD) fell $0.18 and traded at $35.88, down -0.5% for the day, over previous days close. On a weekly basis, the shares are 8.73% over the previous weeks close.
ACADIA Pharmaceuticals (ACAD) : 8 investment research analysts covering ACADIA Pharmaceuticals (ACAD) have an average price target of $49.13 for the near short term. The highest target price given by the Brokerage Firm to the stock is $60 and the lowest target is $40 for the short term. Analysts expect the variance to be within $6.94 of the average price.
ACADIA Pharmaceuticals (NASDAQ:ACAD): stock turned positive on Friday. Though the stock opened at $36.35, the bulls momentum made the stock top out at $37.06 level for the day. The stock recorded a low of $35.65 and closed the trading day at $36.55, in the green by 1.36%. The total traded volume for the day was 1,522,494. The stock had closed at $36.06 in the previous days trading.
In a related news,The (EVP AND GC) of Acadia Pharmaceuticals Inc, Baity Glenn sold 16,000 shares at $35 on July 11, 2016. The Insider selling transaction had a total value worth of $560,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.